Trial Information

Summary: A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to compare the safety and efficacy of Starlix (nateglinide) vs. placebo in patients with type 2 diabetes who are inadequately controlled with basal insulin glargine in combination with metformin and/or thiazolidinedione (pioglitazone or rosiglitazone)

This study is for male and female patients with type 2 diabetes that is not being controlled with regular diabetes medication. Researchers want to find out if a drug called Starlix can help people who are already taking glargin and metformin and/or thiazolidinedione for their type 2 diabetes.

Patient Inclusion Criteria

• Patients must be between 18-78 years of age.
• Patients must have type 2 diabetes, being treated with insulin glargine, metformin and/or thiazolidinedione (TZD).
• Patients must have HbA1C between 7 and 8.5 at screening.

Patient Exclusion Criteria

• Patients must not of had any treatment with any anti-diabetic medication other than glargine, metformin and/or thiazolidinedione (TZD) in the past 3 months.
• Patients must not have Congestive heart failure requiring treatment.
• Patients must not of had a heart attack, coronary artery surgery, or stroke in the past 6 months.
• Patients must not have any liver disease.

For more information,

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 6:30:07 AM